Dual-phase F-18 FDG PET–CT in staging and lymphoscintigraphy for detection of sentinel lymph nodes in oral cavity cancers

Sürücü, Erdem; Polack, Berna; Demir, Yusuf; Durmuşoğlu, Mehmet; Ekmekçi, Sümeyye; Sarıoğlu, Sülen; Çelik, Ahmet; Ada, Emel; İkiz, Ahmet Ömer

doi:10.1016/j.clinimag.2015.02.004

Cited by 4 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, 11 salivary metabolites showed significant correlations with delayed-phase SUV max , but there was no significant correlation between any salivary metabolite and early-phase SUV max . Dual-phase 18 F-FDG PET/CT has recently been used to distinguish between benign lesions and malignant lesions [6,[21][22][23][24]. The SUV max of malignant lesions increased in the delayed phase, whereas FDG uptake in most benign lesions decreased in the delayed phase [21].…”

Section: Discussionmentioning

confidence: 99%

“…The SUV max of malignant lesions increased in the delayed phase, whereas FDG uptake in most benign lesions decreased in the delayed phase [21]. Erdem et al concluded that delayed-phase 18 F-FDG imaging increased the detectability of the primary lesion because of higher FDG uptake by primary tumors in the delayed phase compared to that in the early phase of imaging [6]. Delayed-phase SUV max has the potential to show the aggressiveness of the tumor better than early-phase SUV max .…”

Section: Discussionmentioning

confidence: 99%

“…Generally, a high SUV max indicates a high possibility of malignancy [5]. Recently, dual-phase 18 F-FDG PET/CT has been used as an alternative method when other types of preoperative imaging cannot clearly distinguish between benign and malignant lesions [6][7][8][9]. Thus, both early and delayed SUV max values are important for diagnosing malignancy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Relationship between Standard Uptake Values of Positron Emission Tomography/Computed Tomography and Salivary Metabolites in Oral Cancer: A Pilot Study

Ishikawa

Hiraka

Kirii

et al. 2020

JCM

View full text Add to dashboard Cite

18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) is usually used for staging or evaluation of treatment response rather than for cancer screening. However, 18F-FDG PET/CT has also been used in Japan for cancer screening in people with no cancer symptoms, and accumulating evidence supports this application of 18F-FDG PET/CT. Previously, we have observed a correlation between the saliva and tumor metabolomic profiles in patients with oral cancer. Hence, if salivary metabolites demonstrate a significant correlation with PET parameters such as the maximum standardized uptake value (SUVmax), they may have the potential to be used as a screening tool before PET/CT to identify patients with high SUVmax. Hence, in this study, we aimed to explore the relationship between salivary metabolites and SUVmax of 18F-FDG PET/CT using previously collected data. 18F-FDG PET/CT was performed for staging 26 patients with oral cancer. The collected data were integrated and analyzed along with quantified salivary hydrophilic metabolites obtained from the same patients with oral cancer and controls (n = 44). In total, 11 metabolites showed significant correlations with SUVmax in the delayed phases. A multiple logistic regression model of the two metabolites showed the ability to discriminate between patients with oral cancer and controls, with an area under the receiver operating characteristic curve of 0.738 (p = 0.001). This study uniquely confirmed a relationship between salivary metabolites and SUVmax of PET/CT in patients with oral cancer; salivary metabolites were significantly correlated with SUVmax. These salivary metabolites can be used as a screening tool before PET/CT to identify patients with high SUVmax, i.e., to detect the presence of oral cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Relationship between Standard Uptake Values of Positron Emission Tomography/Computed Tomography and Salivary Metabolites in Oral Cancer: A Pilot Study

Ishikawa

Hiraka

Kirii

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…In order to overcome the overlaps between malignancy and benign lesions, dual-timepoint-imaging (DPI)--at approximately 1 hour (early) and 2 hours (delayed) after injection are recommended [48,49]. Delayed phase of 18 F-FDG imaging may increase primary lesion detectability due to higher FDG uptake in primary tumors compared to the early phase of imaging [50,51]. DPI may also help to differentiate between inflammatory and malignant lymph nodes [52].…”

Section: Sift Deskmentioning

confidence: 99%

PET Imaging in Pancreatic Cancer

Li¹,

Wang²

2019

SDRP-JFST

View full text Add to dashboard Cite

Early accurate detection of pancreatic cancer is still a challenge for current medicine. Compared to conventional anatomical imaging techniques, PET can provide information on tumor function, and PET/CT is increasingly used in detecting and staging of cancer as single "one stop shop" method. In this review, we summarize current PET molecular imaging tracers or probes for pancreatic cancer detection, and a perspective of the future trend of pancreatic cancer target-specific probes in the clinic is also provided.

show abstract

Usefulness of Sentinel Lymph Node Biopsy for Oral Cancer: A Systematic Review and Meta‐Analysis

Kim

et al. 2020

The Laryngoscope

View full text Add to dashboard Cite

Objective We assessed the diagnostic accuracy of sentinel lymph node biopsy (SLNB) for detecting neck nodal metastasis in early oral squamous cell carcinoma (OSCC) as an alternative to elective neck dissection. Study Design A systematic search for relevant literature was conducted in the PubMed, SCOPUS, Embase, Web of Science, and Cochrane databases. Methods Two reviewers individually searched the five databases up to November 2019. For studies that met inclusion criteria, data on patient diagnoses were pooled, including true positives, true negatives, false positives, and false negatives. Methodological quality was checked with the Quality Assessment of Diagnostic Accuracy Studies (version 2) tool. Results In total, 98 observational or retrospective studies were included. The diagnostic odds ratio of SLNB was 326.165 (95% confidence interval [CI]: 231.477–459.587; I2 = 0%). The area under the summary receiver operating characteristic curve was 0.982. Sensitivity was 0.827 (95% CI: 0.804–0.848), and specificity was 0.981 (95% CI: 0.975–0.986). The correlation between sensitivity and the false positive rate was −0.076, which indicates that heterogeneity did not exist. Subgroup analyses were performed with the subgroups reference test type, publication year, and study type. No significant difference was found within the reference test type subgroup. However, differences within the publication year and study type subgroups were significant, where the retrospective study subgroup was significantly more sensitive and specific than the prospective study subgroup. Conclusion Results of this meta‐analysis imply that the high specificity of SLNB supports its role as a diagnostic tool for patients with clinical tumor stage (CT)1‐2 clinically negative (N0) OSCC. More studies should be done to further verify the results of this study. Level of Evidence 2a Laryngoscope, 131:E459–E465, 2021

show abstract

Dual-phase F-18 FDG PET–CT in staging and lymphoscintigraphy for detection of sentinel lymph nodes in oral cavity cancers

Cited by 4 publications

References 28 publications

Relationship between Standard Uptake Values of Positron Emission Tomography/Computed Tomography and Salivary Metabolites in Oral Cancer: A Pilot Study

Relationship between Standard Uptake Values of Positron Emission Tomography/Computed Tomography and Salivary Metabolites in Oral Cancer: A Pilot Study

PET Imaging in Pancreatic Cancer

Usefulness of Sentinel Lymph Node Biopsy for Oral Cancer: A Systematic Review and Meta‐Analysis

Contact Info

Product

Resources

About